Santhera's Omigapil Receives Orphan Drug Designation from FDA and EMEA
18-Aug-2008
In 2007, Santhera licensed omigapil from Novartis for development in Congenital Muscular Dystrophy and other neuromuscular diseases. Tests in a disease-relevant model have shown that SNT-317/omigapil prevents apoptosis and ameliorates the pathology of laminin-alpha 2 deficient muscular dystrophy. Preclinical data will be presented at the upcoming 13th International World Muscle Society Congress in Newcastle, United Kingdom.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.